| Primary |
| Essential Thrombocythaemia |
37.7% |
| Product Used For Unknown Indication |
33.2% |
| Thrombocytosis |
4.9% |
| Myeloproliferative Disorder |
4.5% |
| Hypertension |
4.0% |
| Thrombocythaemia |
2.0% |
| Atrial Fibrillation |
1.2% |
| Cerebrovascular Accident |
1.2% |
| Hyperuricaemia |
1.2% |
| Myelofibrosis |
1.2% |
| Polycythaemia Vera |
1.2% |
| Renal Failure Chronic |
1.2% |
| Thrombosis Prophylaxis |
1.2% |
| Anaemia |
0.8% |
| Chronic Obstructive Pulmonary Disease |
0.8% |
| Peripheral Arterial Occlusive Disease |
0.8% |
| Platelet Aggregation Inhibition |
0.8% |
| Thrombocytopenia |
0.8% |
| Weight Control |
0.8% |
| Back Pain |
0.4% |
|
| Myelofibrosis |
21.0% |
| Acute Coronary Syndrome |
6.5% |
| Myelodysplastic Syndrome |
6.5% |
| Transient Ischaemic Attack |
6.5% |
| Acute Myeloid Leukaemia |
4.8% |
| Anaemia |
4.8% |
| Haematemesis |
4.8% |
| Stress Cardiomyopathy |
4.8% |
| Toxic Epidermal Necrolysis |
4.8% |
| Arteritis Coronary |
3.2% |
| Atrial Thrombosis |
3.2% |
| Cerebral Haemorrhage |
3.2% |
| Chordae Tendinae Rupture |
3.2% |
| Coronary Artery Disease |
3.2% |
| Haematuria |
3.2% |
| Hepatic Function Abnormal |
3.2% |
| Hepatitis |
3.2% |
| Jaundice |
3.2% |
| Malaise |
3.2% |
| Neoplasm Prostate |
3.2% |
|
| Secondary |
| Essential Thrombocythaemia |
34.1% |
| Product Used For Unknown Indication |
21.4% |
| Thrombocytosis |
12.7% |
| Myeloproliferative Disorder |
4.0% |
| Breast Cancer |
3.2% |
| Chronic Obstructive Pulmonary Disease |
3.2% |
| Diabetes Mellitus |
3.2% |
| Hypertension |
3.2% |
| Peripheral Arterial Occlusive Disease |
3.2% |
| Benign Prostatic Hyperplasia |
1.6% |
| Duodenal Ulcer |
1.6% |
| Dyslipidaemia |
1.6% |
| Type 2 Diabetes Mellitus |
1.6% |
| Cardiac Failure |
0.8% |
| Cerebrovascular Accident |
0.8% |
| Hyperuricaemia |
0.8% |
| Platelet Aggregation Inhibition |
0.8% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.8% |
| Thrombocytopenia |
0.8% |
| Thrombosis Prophylaxis |
0.8% |
|
| Hepatic Function Abnormal |
19.0% |
| Anaemia |
9.5% |
| Intracranial Pressure Increased |
9.5% |
| Haematemesis |
7.1% |
| Mallory-weiss Syndrome |
7.1% |
| Acute Coronary Syndrome |
4.8% |
| Gastrointestinal Perforation |
4.8% |
| Malaise |
4.8% |
| Pancytopenia |
4.8% |
| Transient Ischaemic Attack |
4.8% |
| Acute Myeloid Leukaemia |
2.4% |
| Angina Unstable |
2.4% |
| Arrhythmia |
2.4% |
| Atrial Fibrillation |
2.4% |
| Cardio-respiratory Arrest |
2.4% |
| Cerebrovascular Accident |
2.4% |
| Cerebrovascular Disorder |
2.4% |
| Dehydration |
2.4% |
| Gastrointestinal Haemorrhage |
2.4% |
| Haematoma |
2.4% |
|
| Concomitant |
| Chronic Obstructive Pulmonary Disease |
14.3% |
| Myelofibrosis |
10.7% |
| Non-small Cell Lung Cancer |
7.1% |
| Osteoporosis Prophylaxis |
7.1% |
| Pain |
7.1% |
| Antifungal Treatment |
3.6% |
| Bone Disorder |
3.6% |
| Cardiac Failure |
3.6% |
| Cardiovascular Disorder |
3.6% |
| Chronic Myeloid Leukaemia |
3.6% |
| Constipation |
3.6% |
| Essential Thrombocythaemia |
3.6% |
| Gastritis |
3.6% |
| Haemolysis |
3.6% |
| Hypertension |
3.6% |
| Hyperuricaemia |
3.6% |
| Metastases To Bone |
3.6% |
| Paroxysmal Nocturnal Haemoglobinuria |
3.6% |
| Platelet Count Abnormal |
3.6% |
| Prophylaxis |
3.6% |
|
| Dyssomnia |
16.7% |
| Extremity Necrosis |
16.7% |
| Metastases To Bone |
16.7% |
| Oedema Peripheral |
16.7% |
| Product Quality Issue |
16.7% |
| Thrombocytosis |
16.7% |
|
| Interacting |
| Essential Thrombocythaemia |
46.2% |
| Product Used For Unknown Indication |
23.1% |
| Fluid Retention |
15.4% |
| Platelet Count Increased |
15.4% |
|
| Drug Interaction |
80.0% |
| Syncope |
20.0% |
|
